Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Performance of Direct Posterior Composite Restorations in Patients with Amelogenesis Imperfecta.

Operative dentistry·2022
Same author

Clinical Performance of Direct Posterior Composite Restorations in Patients with Amelogenesis Imperfecta.

Operative dentistry·2022
Same author

Digital Technologies to Support Better Outcome and Experience of Care in Patients with Heart Failure.

Current heart failure reports·2022
Same author

The Digital Future of Heart Failure Care.

Current heart failure reports·2022
Same author

COPD and heart failure: differential diagnosis and comorbidity.

Herz·2019
Same author

[Telemonitoring and pulmonary artery pressure-guided treatment of heart failure].

Der Internist·2018
Same journal

High grade cervical intraepithelial neoplasia positive biopsy: the importance of accurate pre-operative workup.

Minerva ginecologica·2021
Same journal

Efficacy and safety of a novel vaginal medical device in recurrent bacterial vaginosis: a multicenter clinical trial.

Minerva ginecologica·2020
Same journal

[Advisory Board Italiano sulla sindrome dell'ovaio policistico (PCOS): dalle osservazioni all'esperienze cliniche sull'uso del mioinositolo (MYO) e dell'acido alfa-lipoico (ALA) per migliorare i quadri della sindrome].

Minerva ginecologica·2020
Same journal

Update on new imaging technologies in sentinel node detection.

Minerva ginecologica·2020
Same journal

Postoperative pelvic dysfunctions associated with the reconstruction of the pelvic floor.

Minerva ginecologica·2020
Same journal

The role of sentinel-node biopsy in ovarian cancer.

Minerva ginecologica·2020
See all related articles

Related Experiment Video

Updated: May 18, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Peripartum cardiomyopathy. An update.

G Güder1, S Brenner, C E Angermann

  • 1Comprehensive Heart Failure Center, University of Würzburg, Würzburg, Germany. Gueder_G@klinik.uni-wuerzburg.de

Minerva Ginecologica
|September 29, 2012
PubMed
Summary
This summary is machine-generated.

Peripartum cardiomyopathy (PPCM) is a rare heart muscle condition affecting pregnant women. This review highlights its varied incidence, unclear causes, and the need for greater awareness among healthcare providers.

Related Experiment Videos

Last Updated: May 18, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Area of Science:

  • Cardiology
  • Obstetrics
  • Genetics

Background:

  • Peripartum cardiomyopathy (PPCM) is a rare heart muscle disease affecting women during pregnancy or postpartum.
  • Symptoms include dyspnea, fluid retention, and signs of cardiac dysfunction.
  • Incidence varies globally, with higher rates in certain populations suggesting genetic or environmental factors.

Purpose of the Study:

  • To review current knowledge on Peripartum Cardiomyopathy (PPCM).
  • To raise awareness of this rare, potentially life-threatening condition among medical professionals.
  • To discuss potential etiologies and emerging therapeutic strategies.

Main Methods:

  • Literature review of Peripartum Cardiomyopathy (PPCM).
  • Synthesis of current data on incidence, risk factors, and clinical presentation.
  • Analysis of proposed pathogenetic mechanisms and treatment approaches.

Main Results:

  • PPCM presents with symptoms of heart failure during late pregnancy or postpartum.
  • Etiology remains unclear, with proposed factors including genetics, autoimmunity, infections, and prolactin activity.
  • Treatment focuses on standard heart failure management, with limited options during pregnancy.

Conclusions:

  • Peripartum Cardiomyopathy (PPCM) requires increased clinical awareness due to its variable presentation and potential for severe outcomes.
  • Further research into its etiology is crucial for developing targeted therapies.
  • Optimal management involves careful monitoring and tailored heart failure treatment, considering fetal safety.